AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age ...Middle East

If approved, linaclotide would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years of age 1 Submission is based on positive Phase 3 study data demonstrating linaclotide (72mcg) resulted in increases in frequency of spontaneous bowel...

Hence then, the article about abbvie submits supplemental new drug application to u s fda to support new indication of linzess linaclotide for functional constipation in children and adolescents 6 to 17 years of age was published today ( Friday 16/12/2022 - 03:56 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age )

Also on site :

• PIN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Pinterest, Inc.
• Sheena Easton, 66, Is Still a Stunning Redhead Several Years After Leaving the Chaos of Mega-Fame Behind
• ‘Murphy Brown’ Star Jessie Jones Dead at 75